Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Breast cancer, early stage

5935 - Serum assessment of non-adherence to adjuvant endocrine therapy (ET) among premenopausal patients in the prospective multicenter CANTO cohort


19 Oct 2018


Proffered paper session - Breast cancer, early stage


Cytotoxic Therapy

Tumour Site

Breast Cancer


Barbara Pistilli


B. Pistilli1, A. PACI2, S. Michiels3, A. ferreira4, V. poinsignon2, P.H. Cottu5, F. Lerebours6, C. Coutant7, A. Lesur8, O. Tredan9, P. Soulie10, L. Vanlemmens11, C. Jouannaud12, C. Levy13, S. Everhard14, P. Arveux7, A.H. Partridge15, S. Delaloge16, F. André17, I. Vaz-Luis18

Author affiliations

  • 1 Breast Cancer Group, GUSTAVE ROUSSY, 94800 - Villejuif/FR
  • 2 Pharmacologist Unit And Sipam, GUSTAVE ROUSSY, 94800 - Villejuif/FR
  • 3 Team Oncostat, Cesp, Gustave Roussy, 94805 - Villejuif/FR
  • 4 Medical Oncology, University of Lisbon, lisbon/PT
  • 5 Medical Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 6 Medical Oncology, Institut Curie Saint Cloud, 92210 - Saint Cloud/FR
  • 7 Medical Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 8 Medical Oncology, Institut de cancérologie de Lorraine, 54519 - Nancy/FR
  • 9 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 10 Medical Oncology, Centre Paul Papin, 49055 - Angers/FR
  • 11 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 12 Medical Oncology, Institut Jean Godinot, 51056 - Reims/FR
  • 13 Medical Oncology, Centre Francois Baclesse, 14076 - Caen/FR
  • 14 Ucbg, UNICANCER, 75654 - Paris/FR
  • 15 Medical Oncology, Dana-Farber Cancer Institute, MA 02215, - Boston/US
  • 16 Medical Oncology, Gustave Roussy, 94805 - Villejuif/FR
  • 17 Breast Cancer Unit, Department Of Medical Oncology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 18 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5935


Previous studies demonstrated that younger patients (pts) with breast cancer (BC) are more likely to be non-adherent to adjuvant ET, leading to impaired prognosis.


The CANTO cohort (NCT01993498) is a French multicenter prospective longitudinal study that will include 12000 pts with recently diagnosed stage I-III BC, to characterize long-term impact of BC treatment toxicities. CANTO COMPLETE, a pre-defined sub study, aims to determine, in premenopausal pts who have been prescribed adjuvant ET, the prevalence and dynamic predictors of non-adherence, at 1 (M12), 3 (M36) and 5 (M60) years, using serum assessment of tamoxifen (TAM) and aromatase-inhibitors (AI) matched with pts’ self-declaration. TAM dosage has been determined by liquid chromatography-tandem mass spectrometry on 200 µL of serum. According to standard definitions, adherence to TAM has been defined as: non-adherent if TAM ≤15 ng/mL (≤40 nM), poorly-adherent if TAM 15-60 ng/mL (40-150 nM) and adherent if > 60 ng/mL (>150 nM).


By December 2017, 11237 pts have been included in CANTO, of whom 1799 (16%) are premenopausal and have been prescribed and agreed to take ET: TAM 1496 (83.2%); TAM + LHRH-analogs (LHRH) 26 (1.4%); AI+LHRH 134 (7.5%); unknown 143 (7.9%).We present here the results of TAM plasma assessment at 1 year on all 1228 pts who reached 1 year of follow-up. Overall, 224 (18.2%) pts appeared not adequately adherent to TAM: 162 (13.2%) non-adherent and 62 (5.0%) poorly-adherent. Matching with pts’ self-declaration and clinical determinants of non-adherence will be presented.


At one year from initiation of TAM, plasma measurements show that a substantial proportion of premenopausal pts are not adequately adherent to this treatment. Poorly-adherent pts could benefit from metabolic and pharmacogenetic investigations. Identification of pts at risk of non-adherence allows early targeted interventions to promote adherence in this unique population.

Clinical trial identification


Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.